Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | CDC25B | P30305 | 4/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338217 | 1.00 | SLC5A2 (0.54) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL338218 | 1.00 | SLC5A2 (0.54) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL17275505 | 0.92 | SLC5A2 (0.61) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL17267512 | 0.92 | SLC5A2 (0.61) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12425949 | 0.89 | SLC5A2 (0.54) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12425878 | 0.89 | SLC5A2 (0.44) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL13201303 | 0.89 | SLC5A2 (0.44) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12425881 | 0.89 | SLC5A2 (0.55) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12425956 | 0.88 | SLC5A2 (0.56) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12601465 | 0.86 | SLC5A2 (0.53) | SLC5A2SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198464-B2 | Method for producing C-glycoside derivative and intermediate for synthesis thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100094025-A1 | METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094025-A1 | METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF | IRS1, IAPP, IDE | SLC5A2 48/4885CHRM1 4182/4885SLC5A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.